Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Slipping Today

By Keith Speights – Oct 29, 2021 at 11:32AM

Key Points

  • Novavax announced it has filed for provisional approval of its COVID-19 vaccine in Australia.
  • However, the good news came on the same day that Politico ran another story critical of the biotech.
  • Novavax says that additional regulatory filings are on the way soon.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors seem to be focusing more on a negative story than they are on Novavax's good news.

What happened

Shares of Novavax (NVAX -4.13%) were slipping 2.8% lower at 11 a.m. EDT on Friday. The company announced earlier in the day that it has filed for provisional approval of its COVID-19 vaccine NVX-CoV2373 in Australia.

Why would the vaccine stock fall on what should be viewed as good news? It wasn't the only news of the day.

Politico published an article Friday morning that was highly critical of Novavax's efforts to develop NVX-CoV2373. The article stated that Novavax's "manufacturing problems have left global distributors without enough shots for poor and middle-income countries."  

A healthcare professional holding a syringe with needle in front of an Australian flag.

Image source: Getty Images.

So what

Investors appear to be giving more weight to Politico's story than to Novavax's regulatory submission in Australia. That could prove to be shortsighted.

Politico had already covered many of the details of Novavax's manufacturing in another piece published last week. But Novavax CEO Stanley Erck made a good point in an interview with Yahoo! News on Wednesday. Erck stated, "You don't file for emergency use approval if you haven't solved all of your manufacturing issues."

That interview came on the heels of Novavax filing for authorization of its COVID-19 vaccine in the United Kingdom. Just as the company had promised, it quickly followed up with the submission in Australia. Erck was and is right: Novavax would be making a colossal blunder if it had not already solved its manufacturing problems prior to these filings. 

Now what

Novavax now plans to complete its regulatory filings for NVX-CoV2373 in several other key markets, including Europe, Canada, and New Zealand. It also anticipates submitting its full package to the U.S. Food and Drug Administration by the end of 2021.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.